RxDoctor Payments DataLook up a doctor →

Richard Berkowitz, MD

Adult Reconstructive Orthopaedic Surgery · Tamarac, FLNPI 1811994544

Payments from drug & device makers

$1,794,621in general payments, 2019–2025

Across 858 payments — averaging $2091.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heron Therapeutics, Inc.$827K
  • Regeneron$439K
  • Janssen Research & Development, LLC$324K
  • Zimmer Biomet$77K
  • Sanofi Pasteur Inc.$49K
  • Stryker$21K
  • plus $57K from 16 others
$8,797in research payments, 2019–2025

Across 23 payments — averaging $382.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$9K

What the payments were for

  • Consulting fees$25,89052%
  • Speaking & faculty fees$8502%
  • Travel & lodging$19,34239%
  • Food & beverage$3,5587%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,794,621 in reported general payments places this provider in the 95th percentile of 96 adult reconstructive orthopaedic surgery providers in Florida.

See all adult reconstructive orthopaedic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$142,108
Medicare patients
207
Services billed
1,968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban89$47,084
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen368$3,717
Cephalexin274$2,787
Celecoxib41$627
Methylprednisolone Acetate16$464
Tramadol Hcl203$452
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen36$323
Clindamycin Hcl34$247
Diclofenac Sodium13$104
Ondansetron Hcl12$62
Meloxicam11$22

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$44$47,08489 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 96 adult reconstructive orthopaedic surgery providers in Florida.

Other adult reconstructive orthopaedic surgery in Tamarac

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →